CAMBRIDGE, England--(BUSINESS WIRE)--FactBio, a developer of novel bioinformatics software with a focus on improving knowledge management and data sharing, has launched its first product, Kusp (Knowledge Sharing Platform).
Kusp is a platform, developed specifically for the life sciences industry, which improves data curation and data discovery using community standards, to improve the use and integration of data. The platform allows users to simplify and accelerate data curation through automation, and the application of advanced data science techniques.
Kusp offers access to a range of reference ontologies and biomedical identifiers for rapid annotation of a user’s biological entities, with a high level of accuracy. The platform is also able to learn new patterns of annotation based on the user’s inputs, improving future performance by learning over time.
The platform can be configured for a range of users. For larger companies, the platform can be deployed behind a firewall, while single users and small to medium enterprises can use a secure cloud based service. Alongside this, Kusp has been designed to integrate with users data at the highest level to ensure data silos are avoided.
Dr James Malone, CEO of FactBio said: “Curation of biomedical data using standards is a hugely valuable step, enabling reuse, sharing, and integration of a data set. Kusp aims to make the process of curation as simple and as rapid as possible. It improves accuracy whilst reducing the cost of what has traditionally been an expensive but important task. Given the volume of data now available, aligning towards community standards, such as in reference ontologies, in cost-effective ways is increasingly important for exploiting the data we have now and in the future.”
FactBio is a developer of bioinformatics software, supporting knowledge management and improved data discovery. Through the Company’s products, users can better exploit experimental data and find relevant sources to accelerate their research. The Company’s founders are using their unique expertise to develop software that will allow companies and organisations to answer new questions with their existing data in areas such as drug development and the understanding of disease mechanisms.